Call for Abstract

Acadamia
  • University of Montreal, Canada

    University of Washington, USA

    Tanzania Vaccine Institute, Tanzania

    Alexandria University, Egypt

    Lanzhou Veterinary Research Institute, China

    Sassari University School of Medicine, Italy

    The University of Melbourne, Australia

    Technical University of Braunschweig, Germany

    Tsukuba Primate Research Center, Japan

    Vaccines and Sera Torlak, Serbia

    Emory University, USA

    Faculdade de Medicina Santo, Brazil

    Centro de Ingenieria Genetica y Biotecnologia, Cuba

    University of KwaZulu-Natal, Belgium

    National Health Research Institute, Taiwan

    Korea University, Korea

    Center for Genetic Engineering and Biotechnology, Cuba

    Indonesian Technical Advisory Committee on Immunization, Indonesia

    Walter Reed Army Institute of Research, USA

    USAMRIID, USA

    Karolinska Institutet, Sweden

    Gulu University, Uganda

    The Royal Children’s Hospital, Australia

    University of Groningen, Netherlands

    Central Institute for Research on Goats, India

    INSERM, France

    University of Sarajevo, Bosnia and Herzegovina

    University of British Columbia, Canada

    Temple University Center for Biotechnology, USA

    UC Davis School of Medicine, USA

    The Scripps Research Institute, USA

    The University of Tokyo, Japan

    Texas Biomedical Research Institute, USA

    Flinders University, Australia

    The George Washington University, USA

    The University of Adelaide, South Australia

    University of Michigan Medical School, USA

    University of Louisville, USA

    National Centre for Biotechnology, Spain

    Pontifical Universtity of Salamanca, Spain

    Universidade Federal de Goias, Brazil

    JJ Strossmayer University, Croatia

    Tehran University of Medical Sciences, Iran

    Medical University of Vienna, Austria

    University of Bedfordshire, UK

    University of Oxford, UK

    The Tazuke Kofukai Medical Research Institute, Japan

    Pasteur Institute of Iran, Iran

    Palacky University, Czech Republic

    The University of Western Ontario, Canada

    Chonbuk National University, South Korea

Business
  • Liquidia Technologies Inc., USA

    Profectus BioSciences, Inc., USA

    Prokarium Ltd., UK

    FluGen Inc., USA

    Novartis Vaccines, USA

    Merck & Co., Inc., USA

    Arbovax Inc., USA

    Merck Millipore, Europe

    Sanofi Pasteur, USA

    UNIVAC llc, Belgium

    Bavarian Nordic, Germany

    VALNEVA, Austria

    Cellular Technology Limited, USA

    Celldex Therapeutics, USA

    Serum Institute of India, India

    Vedantra Pharmaceuticals, USA

    Shanghai Zerun Biotechnology Co .,Ltd. China

    GenPhar Inc., USA

    InnaVirVax, USA

    West Pharmaceutical Services, USA

    Inovio Pharmaceuticals, USA

    VaxInnate Corporation, USA

    Vaxart, Inc., USA

    Iliad Biotechnologies, Scotland

    European Institute of Innovation and Technology, Europe

    REIMS, France

    International Vaccine Institute, Korea

    Micronutrient Initiative, Bangladesh

    Slovak Academy of Sciences, Solvakia

  •  

5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, will be organized around the theme “Vaccine Research: From Bench to Bedside”

Vaccines Asia Pacific-2015 is comprised of 22 tracks and 121 sessions designed to offer comprehensive sessions that address current issues in Vaccines Asia Pacific-2015.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 2-1HIV vaccine
  • Track 2-2Ebola vaccine
  • Track 2-3Cancer vaccination
  • Track 2-4Vaccine for severe acute respiratory syndrome
  • Track 2-5Need of vaccination for major diseases
  • Track 2-6Others
  • Track 3-1Recent trends in vaccines development path
  • Track 3-2Current technologies using in vaccines discovery
  • Track 3-3New vaccines against infectious diseases
  • Track 3-4Recent technologies in modifying bacterial genome
  • Track 4-1Progress and challenges
  • Track 4-2Others
  • Track 5-1Whooping cough Vaccines in pregnant women
  • Track 5-2Immunization before pregnancy
  • Track 5-3Immunization during pregnancy
  • Track 5-4Consequences of halting vaccination in pregnancy
  • Track 5-5Chiropractic vaccination care in women and pregnancy
  • Track 5-6Others
  • Track 6-1Business Development of Animal Vaccines
  • Track 6-2Business Development of Human Vaccines
  • Track 6-3Challenges and Innovation
  • Track 6-4Phyto vaccines
  • Track 6-5Planning
  • Track 7-1Safety considerations in vaccination
  • Track 7-2Vaccines and vaccination knowledge
  • Track 7-3Health care outcomes of different aged people vaccinated
  • Track 7-4Safety and efficacy of vaccines
  • Track 7-5Vaccines and vaccination- health care improvement.
  • Track 7-6Others
  • Track 8-1Tetanus, diphtheria, acellular pertussis vaccine during pregnancy
  • Track 8-2Diphtheria and tetanus toxoids usage in pediatrics
  • Track 8-3Administration and routes of administration of toxoids
  • Track 8-4Innovative toxoid vaccine development
  • Track 8-5Maternal immunization
  • Track 8-6Others
  • Track 9-1Yellow fever: Epidemiology and prevention
  • Track 9-2Typhoid fever vaccination
  • Track 9-3Advantage of live attenuated vaccines
  • Track 9-4Risk factors in unsing live attenuated vaccines
  • Track 9-5Tubercular vaccination
  • Track 9-6Cancer Therapeutic Vaccination
  • Track 9-7Others
  • Track 10-1Animal diseases and vaccination
  • Track 10-2Animal health outcomes
  • Track 10-3Bovine vaccine technology
  • Track 10-4Current status of veterinary vaccines
  • Track 10-5Others
  • Track 10-6Pet vaccines and vaccination
  • Track 11-1Hepatitis B virus spread and control
  • Track 11-2Others
  • Track 11-3Recombinant technology usage
  • Track 11-4Role of nanotechnology in vaccine delivery
  • Track 11-5Vaccines and its target compositions
  • Track 11-6Virus-like particles as vaccines, vectors and adjutants
  • Track 12-1Designing of adjutvants
  • Track 12-2Rationale selection of adjuvants
  • Track 12-3Skin delivery techniques
  • Track 12-4Adjuvant interactions
  • Track 12-5BeneficialAdjuvents
  • Track 12-6Others
  • Track 13-1Major discoveries in carbohydrate based vaccines
  • Track 13-2Glycomics- Vaccine Discoveries
  • Track 13-3Identification, synthesis and evaluation of unique glycan epitopes
  • Track 13-4Targeting the surface carbohydrates of infectious agents
  • Track 13-5Role of carbohydrate-based vaccines in cancer therapy
  • Track 13-6Others
  • Track 14-1Mucosal Vaccines Delivery
  • Track 14-2Mucosal Vaccines Design
  • Track 14-3Others
  • Track 15-1Dendritic cell based vaccines and development
  • Track 15-2Recombinent vector based immunization
  • Track 15-3DNA Vaccination
  • Track 15-4T-cell receptor peptide vaccines
  • Track 15-5Targeted bacterial protein identification
  • Track 15-6Others
  • Track 16-1Immunization and its side effects in geriatrics
  • Track 16-2Vaccine dosing and administration in older adults
  • Track 16-3Herpes zoster vaccine
  • Track 16-4Pneumococcal polysaccharide vaccine
  • Track 16-5Contraindications and precautions during vaccination in geriatrics
  • Track 16-6Risk factors in geriatric immunization
  • Track 16-7Others
  • Track 17-1New approaches to combat bacterial pathogens
  • Track 17-2Public health concerns in vaccination
  • Track 17-3Contraindications of vaccinations
  • Track 17-4Vaccines formulation and technologies used in conjugated vaccines
  • Track 17-5Vaccine resistance and need of Next-Gen Conjugate Vaccines
  • Track 17-6Others
  • Track 18-1Others
  • Track 18-2Peptide Based vaccines
  • Track 18-3Protein based vaccines
  • Track 19-1Conjugated vaccine discovery and translation of new vaccine technology
  • Track 19-2Effect of pneumococcal conjugate vaccine on pneumococcal meningitis
  • Track 19-3Manufacturing of Conjugate Vaccines
  • Track 19-4Others
  • Track 19-5Production of Conjugate Vaccines Using Recombinant DNA Technology
  • Track 19-6Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants
  • Track 20-1Chickenpox vaccines
  • Track 20-2Diphtheria vaccines
  • Track 20-3Polio vaccines
  • Track 20-4Hib Vaccines
  • Track 20-5Hepatitis A vaccines
  • Track 20-6Hepatitis B vaccines
  • Track 20-7Flu vaccines
  • Track 20-8Measles vaccines
  • Track 20-9Mumps vaccines
  • Track 20-10Pertussis vaccines
  • Track 20-11Pneumococcal vaccines
  • Track 20-12Rotavirus vaccines
  • Track 20-13Rubella vaccines
  • Track 20-14Tetanus vaccines
  • Track 20-15Others
  • Track 21-1Cancer Therapeutic Vaccines
  • Track 21-2Vaccines for Preventive cancer
  • Track 21-3Others
  • Track 22-1Preclinical stage development and factors affecting
  • Track 22-2Clinical stage process
  • Track 22-3Vaccines efficacy testing
  • Track 22-4Manufacture of the vaccine to Good Manufacturing Practice standards
  • Track 22-5Complications and consequences affecting vaccine development
  • Track 22-6Others